January 22, 2021 by Chain Drug Review
Chip Davis, COVID-19, HDA, health care distribution industry
Leading Headlines, Pharmacy

ARLINGTON, Va. — HDA president and CEO Chester “Chip” Davis, Jr., released the following statement in response to recent commentary related to the COVID-19 vaccination effort: “HDA and the health care distribution industry are committed to doing whatever is necessary to assist the Biden administration in meeting its goal of administering 100 million vaccines to
December 22, 2020 by Chain Drug Review
Chip Davis, COVID-19 emergency relief package, HDA
Pharmacy

ARLINGTON, Va. — HDA president and CEO Chester “Chip” Davis, Jr., released a statement commenting on passage of the COVID-19 emergency relief package by the U.S. House of Representatives and the U.S. Senate. “HDA applauds Congress for passing the bipartisan economic stimulus package that will provide much needed relief to the businesses and millions of
December 11, 2020 by Chain Drug Review
Chip Davis, COVID-19 vaccine, HDA
Pharmacy

ARLINGTON, Va. — HDA president and CEO Chester “Chip” Davis, Jr., released the following statement on the U.S. Food and Drug Administration’s (FDA) decision to grant Emergency Use Authorization of the first COVID-19 vaccine, manufactured by Pfizer and BioNTech: “Today’s decision by the FDA marks a historic turning point in the fight against this global
June 11, 2020 by Chain Drug Review
Chip Davis, COVID-19, HDA, supply chain
Leading Headlines, Pharmacy

ARLINGTON, Va. — The Healthcare Distribution Alliance (HDA) released policy principles reaffirming the pharmaceutical distribution industry’s commitment to assisting the country and frontline healthcare providers during pandemics and public health emergencies. HDA highlights four priority areas: Supply Chain Coordination: Coordination between the public and private sector is key to addressing public health crises. Accordingly, a consolidated contact within the
June 2, 2020 by Brian Bossetta
Chip Davis, COVID-19, HDA, HDA (formerly known as the Healthcare Distribution Management Association)
Leading Headlines, News, Pharmacy, Supplier News

ARLINGTON, Va. — Taking on a new leadership role is never easy; taking the helm during a global pandemic, however, especially when job No. 1 for the organization’s members involves keeping the country’s vital medical supply chain running smoothly, defines daunting. But being named president and chief executive officer of the Healthcare Distribution Alliance
May 20, 2020 by Chain Drug Review
Chip Davis, COVID-19, HDA
Leading Headlines, Pharmacy, Supplier News

ARLINGTON, Va. — HDA has released a two-minute video that further reinforces the pharmaceutical distribution industry’s critical function as it adapts and rises to the challenge of COVID-19, while also continuing the vital work of delivering the medicines Americans rely on to manage their daily health care needs. The video features HDA president and CEO
April 28, 2020 by Chain Drug Review
Chip Davis, COVID-19, HDA (formerly known as the Healthcare Distribution Management Association)
Leading Headlines, Pharmacy

ARLINGTON, Va.— On April 27, HDA president and CEO Chester “Chip” Davis, sent a letter to the leadership of major pharmacy organizations to underscore how individual distributors typically manage, and are adapting to, the unprecedented supply challenges presented by COVID-19. Recipients included: American Association of Colleges of Pharmacy; American Pharmacists Association; American Society of Health-System Pharmacists;
April 17, 2020 by Chip Davis
Chip Davis, COVID-19, HDA
Opinion

Across the country, brave, frontline health care professionals are working around the clock as our nation grapples with the COVID-19 pandemic. These workers — the true heroes of the pandemic — are treating patients, maintaining vital health care operations and serving as emergency responders. In this time of crisis, it is also important to remember
March 9, 2020 by Chain Drug Review
Chip Davis, Healthcare Distribution Alliance (HDA)
Leading Headlines

ARLINGTON, Va. – In response to the Food and Drug Administration’s (FDA) proposed rule on prescription drug importation, Healthcare Distribution Alliance (HDA) president and CEO Chester “Chip” Davis, Jr. released the following statement: “As the vital link within the healthcare ecosystem, HDA’s pharmaceutical distributor members share FDA’s commitment to ensuring that Americans have access to
February 10, 2020 by Chain Drug Review
Chip Davis, Greg Drew, HDA, John Gray, The Healthcare Distribution Alliance (HDA) board of directors’ executive committee
Leading Headlines, Pharmacy

ARLINGTON, Va. — The Healthcare Distribution Alliance (HDA) board of directors’ executive committee announced Monday the appointment of Chester “Chip” Davis, to the position of president and chief executive officer. Davis will join HDA during March of this year. He joins HDA coming from the Association for Accessible Medicines (AAM), the nation’s leading trade association
January 10, 2020 by Chip Davis
Association for Accessible Medicines, Chip Davis
Issue 01-06-2020, Opinion

The public continues to name health care costs — and prescription drugs in particular — as a top priority. A recent survey from the Kaiser Family Foundation found that eight in 10 Americans say the cost of prescription drugs is unreasonable. At the same time, the value of generic medicines is well established. Consider this:
January 22, 2019 by Chip Davis
Association for Accessible Medicines, Chip Davis
Featured Articles, Issue 01-07-2019, Leading Headlines, Pharmacy

Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. This past June, Secretary of Health and Human Services Alex Azar told the Senate Finance Committee, “We need a strong, robust generic market.” He followed this statement with an observation that resonated for many of the member companies of the
June 12, 2017 by Geoff Walden and Chain Drug Review
2017 AAM Generic Drug Access & Savings in the U.S., AAM, Association for Accessible Medicines, Chip Davis, generic drugs, Prescription abandonment
Featured Articles, Leading Headlines, Pharmacy, Supplier News

WASHINGTON — Prescription abandonment is sharply higher for branded drugs than generic drugs, a new annual report commissioned by the Association for Accessible Medicines (AAM) found. AAM said Monday that abandonment — defined as the failure to pick up a new script — was nearly three times as high for brand-name drugs as for generics
June 9, 2017 by CDR Blog and Chain Drug Review
AAM, Alex Brill, Association for Accessible Medicines, Chip Davis, Matrix Global Advisors, new generic drugs, Pharmaceutical Research and Manufacturers of America, PhRMA, REMS, REMS and Restricted Distribution Programs, Risk Evaluation Mitigation Strategies
CDR Blog

The Association for Accessible Medicines (AAM) said a new report shows that abuse of the Food and Drug Administration’s Risk Evaluation Mitigation Strategies (REMS) safety program is hampering the market entry of new generic drugs. This week, AAM said a report by Alex Brill, CEO of economic policy consultancy Matrix Global Advisors, titled “REMS and